SABCS 2022 | Interrupting endocrine therapy in woman with endocrine responsive breast cancer
Olivia Pagani, MD, Institute of Oncology of Southern Switzerland, Ticino, Switzerland, provides an overview of the POSITIVE (NCT02308085) trial designed to prospectively evaluate the safety and pregnancy outcomes of temporarily interrupting endocrine therapy for woman hormone responsive breast cancer desiring a pregnancy. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So, the POSITIVE trial wanted to address a very important question for young women who had breast cancer and who are interested in pregnancy after breast cancer. And we had a lot of retrospective data suggesting that a pregnancy after breast cancer is not detrimental for breast cancer outcomes. But this data were mixed, were maybe biased by the healthy mother effect, by many other potential biases...
So, the POSITIVE trial wanted to address a very important question for young women who had breast cancer and who are interested in pregnancy after breast cancer. And we had a lot of retrospective data suggesting that a pregnancy after breast cancer is not detrimental for breast cancer outcomes. But this data were mixed, were maybe biased by the healthy mother effect, by many other potential biases. So, POSITIVE is the first and unique prospective trial to address this question.
Read more...
